

Grennady Wirjanata

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5678262/grennady-wirjanata-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,053
citations

15
h-index

32
g-index

33
ext. papers

1,281
ext. citations

9.7
avg, IF

3.06
L-index

#	Paper	IF	Citations
30	A novel multiple-stage antimalarial agent that inhibits protein synthesis. <i>Nature</i> , 2015 , 522, 315-20	50.4	250
29	Quinolone-3-diarylethers: a new class of antimalarial drug. <i>Science Translational Medicine</i> , 2013 , 5, 177ra37.5	37.5	150
28	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 5060-7	5.9	101
27	Pyrazoleamide compounds are potent antimalarials that target Na ⁺ homeostasis in intraerythrocytic <i>Plasmodium falciparum</i> . <i>Nature Communications</i> , 2014 , 5, 5521	17.4	85
26	Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	81
25	A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. <i>ACS Infectious Diseases</i> , 2016 , 2, 945-957	5.5	55
24	A tetraoxane-based antimalarial drug candidate that overcomes PFK13-C580Y dependent artemisinin resistance. <i>Nature Communications</i> , 2017 , 8, 15159	17.4	44
23	Submicroscopic and Asymptomatic <i>Plasmodium Parasitaemia</i> Associated with Significant Risk of Anaemia in Papua, Indonesia. <i>PLoS ONE</i> , 2016 , 11, e0165340	3.7	38
22	Comparative ex vivo activity of novel endoperoxides in multidrug-resistant <i>plasmodium falciparum</i> and <i>P. vivax</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5258-63	5.9	34
21	Cellular thermal shift assay for the identification of drug-target interactions in the <i>Plasmodium falciparum</i> proteome. <i>Nature Protocols</i> , 2020 , 15, 1881-1921	18.8	27
20	UCT943, a Next-Generation <i>Plasmodium falciparum</i> PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	25
19	Effective preparation of <i>Plasmodium vivax</i> field isolates for high-throughput whole genome sequencing. <i>PLoS ONE</i> , 2013 , 8, e53160	3.7	24
18	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. <i>PLoS Medicine</i> , 2016 , 13, e1002138	11.6	24
17	Expression of <i>Plasmodium vivax</i> crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 361-7	5.9	20
16	Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6117-24	5.9	15
15	Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017 , 97, 1788-1796	3.2	12
14	Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant <i>Plasmodium falciparum</i> and <i>P. vivax</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5721-6	5.9	11

13	3,3-Disubstituted 5,5-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 2485-2498	8.3	10
12	Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry. <i>Malaria Journal</i> , 2015 , 14, 417	3.6	10
11	Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms. <i>Malaria Journal</i> , 2016 , 15, 137	3.6	9
10	Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	7
9	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0008295	4.8	5
8	A comprehensive RNA handling and transcriptomics guide for high-throughput processing of Plasmodium blood-stage samples. <i>Malaria Journal</i> , 2020 , 19, 363	3.6	3
7	The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to parasite resistance. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	3
6	Longitudinal ex vivo and molecular trends of chloroquine and piperazine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. <i>International Journal for Parasitology: Drugs and Drug</i>	4	0
5	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
4	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
3	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
2	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		
1	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia 2020 , 14, e0008295		